All posts by: Michael Zand

FDA approves 2nd gene therapy for blood cancer, this one for aggressive lymphoma in adults – Chicago Tribune

Chicago TribuneFDA approves 2nd gene therapy for blood cancer, this one for aggressive lymphoma in adultsChicago TribuneU.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lym… Continue reading

US regulators approve 2nd gene therapy for blood cancer – ABC News

ForbesUS regulators approve 2nd gene therapy for blood cancerABC NewsOn Wednesday, Oct. 18, 2017, the Food and Drug Administration approved sales of the therapy Yescarta, developed by Kite Pharma. It is the second gene therapy for U.S. patients _ the f… Continue reading

City of Hope, Leading Cancer Research and Treatment Center, to Provide First-Ever FDA-Approved CAR-T Cell … – Business Wire (press release)

FDA Approves Axi-Cel for Large B-cell Lymphoma – Targeted Oncology

FDA Approves Axi-Cel for Large B-cell LymphomaTargeted OncologyThe FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed or refractory large B-cell lymphoma, making the agent the second approved … Continue reading

FDA Approves Second LLS-Supported CAR T-cell Immunotherapy, A Revolutionary Approach to Cancer Treatment – PR Newswire (press release)

FDA Approves Second LLS-Supported CAR T-cell Immunotherapy, A Revolutionary Approach to Cancer TreatmentPR Newswire (press release)The therapy, axicabtagene ciloleucel (Yescarta ™), is the second of this new method of treatment, known as CAR (chimeric … Continue reading

New gene-altering treatment offered for certain blood cancers – Washington University School of Medicine in St. Louis

Washington University School of Medicine in St. LouisNew gene-altering treatment offered for certain blood cancersWashington University School of Medicine in St. LouisAmanda Cashen, MD, examines patient Marie Miceli at Siteman Cancer Center at Barnes-… Continue reading